BXMPY (Beximco Pharmaceuticals) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Beximco Pharmaceuticals 5-Year Yield-on-Cost %?

Beximco Pharmaceuticals BXMPY 94 5-Year Yield-on-Cost % is 0.00 as of Jul. 21, 2026. GuruFocus rates BXMPY with a GF Score™ of 94/100. The stock has 5 warning signs investors should review. Among 513 Drug Manufacturers companies, Beximco Pharmaceuticals ranks worse than 194931.58% on this metric.

Beximco Pharmaceuticals's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Beximco Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:


During the past 13 years, Beximco Pharmaceuticals's highest Yield on Cost was 17.20. The lowest was 1.36. And the median was 5.74.


BXMPY's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.29
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Beximco Pharmaceuticals  (OTCPK:BXMPY) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Beximco Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

BXMPY vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beximco Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's 5-Year Yield-on-Cost % falls into.


Beximco Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Beximco Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Beximco Pharmaceuticals (BXMPY) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 21, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Beximco Pharmaceuticals and its competitors. Over the past decade, Beximco Pharmaceuticals' 5-Year Yield-on-Cost % has ranged from 1.36 to 17.20. According to the industry distribution chart, Beximco Pharmaceuticals ranks #999999 out of 513 companies in the Drug Manufacturers industry.
Is Beximco Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Beximco Pharmaceuticals' current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 1.36 to a high of 17.20. Based on the distribution chart, Beximco Pharmaceuticals ranks #999999 out of 513 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Beximco Pharmaceuticals has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #999999 out of 513 companies for 5-Year Yield-on-Cost %. This places Beximco Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. Historically, Beximco Pharmaceuticals' own 5-Year Yield-on-Cost % has ranged from 1.36 to 17.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Beximco Pharmaceuticals' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.